Pim-1 Kinase Phosphorylates and Stabilizes 130 KDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Sep 17

PMID 24040307

Citations 37

Authors

Karthika Natarajan

Yingqiu Xie

Mehmet Burcu

Douglas E Linn

Yun Qiu

Maria R Baer

Affiliations

Soon will be listed here.

Abstract

The type III receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3) is expressed on both normal hematopoietic stem cells and acute myeloid leukemia (AML) cells and regulates their proliferation. Internal tandem duplication (ITD) mutation of FLT3 is present in a third of AML cases, results in constitutive activation and aberrant signaling of FLT3, and is associated with adverse treatment outcomes. While wild-type (WT) FLT3 is predominantly a 150 kDa complex glycosylated cell surface protein, FLT3-ITD is partially retained in the endoplasmic reticulum as a 130 kDa underglycosylated species associated with the chaperones calnexin and heat shock protein (HSP) 90, and mediates aberrant STAT5 signaling, which upregulates the oncogenic serine/threonine kinase Pim-1. FLT3 contains a Pim-1 substrate consensus serine phosphorylation site, and we hypothesized that it might be a Pim-1 substrate. Pim-1 was indeed found to directly interact with and serine-phosphorylate FLT3. Pim-1 inhibition decreased the expression and half-life of 130 kDa FLT3, with partial abrogation by proteasome inhibition, in association with decreased FLT3 binding to calnexin and HSP90, and increased 150 kDa FLT3 expression and half-life, with abrogation by inhibition of glycosylation. These findings were consistent with Pim-1 stabilizing FLT3-ITD as a 130 kDa species associated with calnexin and HSP90 and inhibiting its glycosylation to form the 150 kDa species. Pim-1 knockdown effects were similar. Pim-1 inhibition also decreased phosphorylation of FLT3 at tyrosine 591 and of STAT5, and expression of Pim-1 itself, consistent with inhibition of the FLT3-ITD-STAT5 signaling pathway. Finally, Pim-1 inhibition synergized with FLT3 inhibition in inducing apoptosis of FLT3-ITD cells. This is, to our knowledge, the first demonstration of a role of Pim-1 in a positive feedback loop promoting aberrant signaling in malignant cells.

Citing Articles

Importance of PTM of FLT3 in acute myeloid leukemia.

Liu J, Gu J Acta Biochim Biophys Sin (Shanghai). 2024; 56(8):1199-1207.

PMID: 38915288 PMC: 11399421. DOI: 10.3724/abbs.2024112.

Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.

Lee J, Chatterjee A, Scarpa M, Bailey C, Niyongere S, Singh P Cancer Res Commun. 2024; 4(2):431-445.

PMID: 38284896 PMC: 10870818. DOI: 10.1158/2767-9764.CRC-23-0379.

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.

Pousse L, Korfi K, Medeiros B, Berrera M, Kumpesa N, Eckmann J Front Oncol. 2023; 13:1150149.

PMID: 37205201 PMC: 10185852. DOI: 10.3389/fonc.2023.1150149.

Targeting Pim kinases in hematological cancers: molecular and clinical review.

Bellon M, Nicot C Mol Cancer. 2023; 22(1):18.

PMID: 36694243 PMC: 9875428. DOI: 10.1186/s12943-023-01721-1.

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.

Song M, Park B, Uhm J Int J Mol Sci. 2022; 23(20).

PMID: 36293564 PMC: 9604443. DOI: 10.3390/ijms232012708.

References

Shay K, Wang Z, Xing P, McKenzie I, Magnuson N . Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res. 2005; 3(3):170-81. DOI: 10.1158/1541-7786.MCR-04-0192. View

Cuypers H, Selten G, Quint W, Zijlstra M, Maandag E, Boelens W . Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984; 37(1):141-50. DOI: 10.1016/0092-8674(84)90309-x. View

Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M . Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28(11):1856-62. PMC: 2930809. DOI: 10.1200/JCO.2009.25.4888. View

Baek S, Kang N, Popowicz G, Arciniega M, Jung S, Byun S . Structural and functional analysis of the natural JNK1 inhibitor quercetagetin. J Mol Biol. 2012; 425(2):411-23. PMC: 3540140. DOI: 10.1016/j.jmb.2012.10.019. View

Zhang Y, Wang Z, Magnuson N . Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res. 2007; 5(9):909-22. DOI: 10.1158/1541-7786.MCR-06-0388. View

Wang X, Yue P, Kim Y, Fu H, Khuri F, Sun S . Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 2008; 68(18):7409-18. PMC: 2562339. DOI: 10.1158/0008-5472.CAN-08-1522. View

Hart G, Slawson C, Ramirez-Correa G, Lagerlof O . Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011; 80:825-58. PMC: 3294376. DOI: 10.1146/annurev-biochem-060608-102511. View

Muraski J, Fischer K, Wu W, Cottage C, Quijada P, Mason M . Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload. Proc Natl Acad Sci U S A. 2008; 105(37):13889-94. PMC: 2544549. DOI: 10.1073/pnas.0709135105. View

Aho T, Sandholm J, Peltola K, Mankonen H, Lilly M, Koskinen P . Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004; 571(1-3):43-9. DOI: 10.1016/j.febslet.2004.06.050. View

10.

Kim K, Baird K, Ahn J, Meltzer P, Lilly M, Levis M . Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2004; 105(4):1759-67. DOI: 10.1182/blood-2004-05-2006. View

11.

Ramos R, Swanson A, Bass J . Calreticulin and Hsp90 stabilize the human insulin receptor and promote its mobility in the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2007; 104(25):10470-5. PMC: 1965537. DOI: 10.1073/pnas.0701114104. View

12.

Kim K, Baird K, Davis S, Piloto O, Levis M, Li L . Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol. 2007; 138(5):603-15. DOI: 10.1111/j.1365-2141.2007.06696.x. View

13.

Xie Y, Xu K, Linn D, Yang X, Guo Z, Shimelis H . The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2007; 283(6):3349-3356. DOI: 10.1074/jbc.M707773200. View

14.

Xie Y, Burcu M, Linn D, Qiu Y, Baer M . Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol. 2010; 78(2):310-8. PMC: 11037423. DOI: 10.1124/mol.109.061713. View

15.

Schmidt-Arras D, Bohmer S, Koch S, Muller J, Blei L, Cornils H . Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood. 2009; 113(15):3568-76. DOI: 10.1182/blood-2007-10-121426. View

16.

Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh J . Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007; 6(1):163-72. DOI: 10.1158/1535-7163.MCT-06-0397. View

17.

Quentmeier H, Reinhardt J, Zaborski M, Drexler H . FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003; 17(1):120-4. DOI: 10.1038/sj.leu.2402740. View

18.

Rocnik J, Okabe R, Yu J, Lee B, Giese N, Schenkein D . Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood. 2006; 108(4):1339-45. PMC: 1895880. DOI: 10.1182/blood-2005-11-011429. View

19.

Saris C, Domen J, Berns A . The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 1991; 10(3):655-64. PMC: 452698. DOI: 10.1002/j.1460-2075.1991.tb07994.x. View

20.

George P, Bali P, Cohen P, Tao J, Guo F, Sigua C . Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004; 64(10):3645-52. DOI: 10.1158/0008-5472.CAN-04-0006. View